drugset / Trial / NCT03238027
A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
A Phase 1 dose escalation study to determine if axatilimab as monotherapy and axatilimab in combination with a fixed dose of durvalumab will be sufficiently safe and well-tolerated at biologically active doses to warrant further investigation in patients with solid tumors.
Timeline
- Start
- 2017-09-01
- Primary completion
- 2020-11-20
- Completion
- 2020-11-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axatilimab | Monoclonal antibody | 1 mg/kg | — |
| Subject | Axatilimab | Monoclonal antibody | 2 mg/kg | — |
| Subject | Axatilimab | Monoclonal antibody | 3 mg/kg | — |
| Subject | Axatilimab | Monoclonal antibody | 6 mg/kg | — |
| Subject | Axatilimab | Monoclonal antibody | 10 mg/kg | — |
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | — |